
Xiaojian Zhu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1258848/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis, 2020, 18, 844-847.	3.8	4,615
2	Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis, 2020, 18, 1094-1099.	3.8	2,925
3	Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. Journal of Thrombosis and Thrombolysis, 2021, 51, 1107-1110.	2.1	359
4	miR-146b-5p within BCR-ABL1–Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells. Cancer Research, 2016, 76, 2901-2911.	0.9	88
5	COVID-19 in persons with chronic myeloid leukaemia. Leukemia, 2020, 34, 1799-1804.	7.2	74
6	Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies. Journal of Controlled Release, 2020, 326, 455-467.	9.9	54
7	miR-638 Regulates Differentiation and Proliferation in Leukemic Cells by Targeting Cyclin-dependent Kinase 2. Journal of Biological Chemistry, 2015, 290, 1818-1828.	3.4	50
8	Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma. , 2019, 7, 315.		47
9	Disulfiram/copper targets stem cellâ€like ALDH ⁺ population of multiple myeloma by inhibition of ALDH1A1 and Hedgehog pathway. Journal of Cellular Biochemistry, 2018, 119, 6882-6893.	2.6	39
10	CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. Frontiers in Oncology, 2020, 10, 1306.	2.8	32
11	Sequential CD19/22 CAR T-cell immunotherapy following autologous stem cell transplantation for central nervous system lymphoma. Blood Cancer Journal, 2021, 11, 131.	6.2	28
12	ANP32A regulates histone H3 acetylation and promotes leukemogenesis. Leukemia, 2018, 32, 1587-1597.	7.2	25
13	Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy. Blood, 2020, 136, 516-519.	1.4	25
14	Leukemia cell-derived microvesicles induce T cell exhaustion via miRNA delivery. OncoImmunology, 2018, 7, e1448330.	4.6	24
15	Validation of the PLASMIC score, a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis, in Chinese patients. Thrombosis Research, 2018, 172, 9-13.	1.7	23
16	Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study. Experimental Hematology and Oncology, 2020, 9, 29.	5.0	22
17	Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation. Frontiers in Oncology, 2021, 11, 643382.	2.8	21
18	c-MYC and reactive oxygen species play roles in tetrandrine-induced leukemia differentiation. Cell Death and Disease, 2018, 9, 473.	6.3	20

Χιαομίαν Ζημ

#	Article	IF	CITATIONS
19	Chidamide Inhibits Acute Myeloid Leukemia Cell Proliferation by lncRNA VPS9D1-AS1 Downregulation via MEK/ERK Signaling Pathway. Frontiers in Pharmacology, 2020, 11, 569651.	3.5	19
20	A novel chimeric antigen receptor redirecting T-cell specificity towards CD26+ cancer cells. Leukemia, 2021, 35, 119-129.	7.2	15
21	Characteristics of emergency patients with markedly elevated D-dimer levels. Scientific Reports, 2020, 10, 7784.	3.3	14
22	Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia. Signal Transduction and Targeted Therapy, 2020, 5, 21.	17.1	13
23	The Value of Thromboelastography for Bleeding Risk Prediction in Hematologic Diseases. American Journal of the Medical Sciences, 2016, 352, 502-506.	1.1	12
24	Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation. Frontiers in Immunology, 2021, 12, 653030.	4.8	12
25	Tumor-derived extracellular vesicles induce invalid cytokine release and exhaustion of CD19 CAR-T Cells. Cancer Letters, 2022, 536, 215668.	7.2	11
26	Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia. PLoS ONE, 2016, 11, e0147545.	2.5	10
27	Absolute Eosinophil Count Predicts Intensive Care Unit Transfer Among Elderly COVID-19 Patients From General Isolation Wards. Frontiers in Medicine, 2020, 7, 585222.	2.6	10
28	Clinical and immunological features of platelet transfusion refractoriness in young patients with de novo acute myeloid leukemia. Cancer Medicine, 2020, 9, 4941-4948.	2.8	10
29	A twoâ€part, singleâ€arm, multicentre, phase I study of zanubrutinib, a selective <scp>Bruton tyrosine kinase</scp> inhibitor, in Chinese patients with relapsed/refractory Bâ€cell malignancies. British Journal of Haematology, 2022, 198, 62-72.	2.5	10
30	Role of extracellular regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937. Journal of Huazhong University of Science and Technology [Medical Sciences], 2004, 24, 45-47.	1.0	9
31	Monitoring of leukemia stem cells in chronic myeloid leukemia patients. Leukemia and Lymphoma, 2018, 59, 2264-2266.	1.3	9
32	T cells expressing CD26-specific chimeric antigen receptors exhibit extensive self-antigen-driven fratricide. Immunopharmacology and Immunotoxicology, 2019, 41, 490-496.	2.4	9
33	Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0158827.	2.5	9
34	Prognosis of Patients With de novo Acute Myeloid Leukemia Resistant to Initial Induction Chemotherapy. American Journal of the Medical Sciences, 2016, 351, 473-479.	1.1	8
35	ANP32A dysregulation contributes to abnormal megakaryopoiesis in acute megakaryoblastic leukemia. Blood Cancer Journal, 2017, 7, 661.	6.2	8
36	<p>Tumor necrosis factor α knockout impaired tumorigenesis in chronic myeloid leukemia cells partly by metabolism modification and miRNA regulation</p> . OncoTargets and Therapy, 2019, Volume 12, 2355-2364.	2.0	8

Χιαομίαν Ζημ

#	Article	IF	CITATIONS
37	The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia. Leukemia and Lymphoma, 2020, 61, 128-137.	1.3	8
38	Efficacy and Safety of Orelabrutinib in Relapsed/Refractory Waldenstrom's Macroglobulinemia Patients. Blood, 2021, 138, 46-46.	1.4	8
39	Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. Frontiers in Immunology, 2022, 13, .	4.8	8
40	Comparison of chronic myeloid leukemia stem cells and hematopoietic stem cells by global proteomic analysis. Biochemical and Biophysical Research Communications, 2020, 522, 362-367.	2.1	7
41	Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia. International Journal of Cardiology, 2020, 306, 163-167.	1.7	7
42	Case Report: Multi-Omics Analysis and CAR-T Treatment of a Chronic Myeloid Leukemia Blast Crisis Case 5 Years After the Discontinuation of TKI. Frontiers in Oncology, 2021, 11, 739871.	2.8	7
43	A clinical observation of Chinese chronic myelogenous leukemia patients after discontinuation of tyrosine kinase inhibitors. Oncotarget, 2016, 7, 58234-58243.	1.8	7
44	P-450-dependent epoxygenase pathway of arachidonic acid is involved in myeloma-induced angiogenesis of endothelial cells. Journal of Huazhong University of Science and Technology [Medical Sciences], 2011, 31, 596-601.	1.0	6
45	A folate receptor 3 SNP promotes mitochondriaâ€induced clonogenicity of CML leukemia cells: Implications for treatment free remission. Clinical and Translational Medicine, 2021, 11, e317.	4.0	6
46	The Prognostic Value of D-Dimer in De Novo Acute Myeloid Leukemia. American Journal of the Medical Sciences, 2016, 352, 129-133.	1.1	5
47	The role of thromboelastography in predicting bleeding risk and guiding the administration of platelet transfusions in hematological patients: a cohort study. Annals of Hematology, 2016, 95, 1163-1168.	1.8	5
48	Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e545-e550.	0.4	5
49	Concurrent hematoma and venous thrombosis in a patient with autoimmune acquired factor XIII deficiency. International Journal of Laboratory Hematology, 2020, 42, e4-e6.	1.3	5
50	Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, e382-e391.	0.4	5
51	Dynamic changes in peripheral blood lymphocyte subset counts and functions in patients with diffuse large B cell lymphoma during chemotherapy. Cancer Cell International, 2021, 21, 282.	4.1	5
52	The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation. Stem Cells and Development, 2019, 28, 1480-1485.	2.1	4
53	Two cases of von Willebrand disease type 3 in consanguineous Chinese families. Molecular Genetics & Genomic Medicine, 2020, 8, e1075.	1.2	4
54	T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma. Frontiers in Immunology, 2022, 13, 873789.	4.8	4

Χιαοjιαν Ζημ

#	Article	IF	CITATIONS
55	Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays. American Journal of the Medical Sciences, 2017, 354, 22-26.	1.1	3
56	Evaluation of lymphocyte function by IFN-γ secretion capability assay in the diagnosis of lymphoma-associated hemophagocytic syndrome. Human Immunology, 2019, 80, 1006-1011.	2.4	3
57	Determining the cutoff value of the APTT mixing test for factor VIII inhibitor. Clinical Chemistry and Laboratory Medicine, 2019, 57, e88-e90.	2.3	3
58	Regulative function of telomerase and extracelluar regulated protein kinases to leukemic cell apoptosis. Journal of Huazhong University of Science and Technology [Medical Sciences], 2002, 22, 292-294.	1.0	2
59	The epigenetic effect of microRNA in BCR-ABL1-positive microvesicles during the transformation of normal hematopoietic transplants. Oncology Reports, 2017, 38, 3278-3284.	2.6	2
60	Saline is a more appropriate solution for microvesicles for flow cytometric analyses. Oncotarget, 2017, 8, 34576-34585.	1.8	2
61	Significantly prolonged <scp>PT</scp> and <scp>APTT</scp> could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disorders. International Journal of Laboratory Hematology, 2019, 41, e23-e26.	1.3	2
62	Rapid genotyping of F8 intron 22 inversion by nested PCR based on long-distance PCR. Journal of Thrombosis and Thrombolysis, 2020, 49, 591-601.	2.1	2
63	Congenital fibrinogen disorder caused by digenic mutations of the FGA and FGB genes. Hematology, 2020, 25, 145-148.	1.5	2
64	A Case of Severe COVID-19 in a Patient with Acute Graft-versus-Host Disease after Haploidentical Transplantation. Case Reports in Hematology, 2021, 2021, 1-5.	0.4	2
65	Effect of siRNA targeting Ets2 gene on chemosensitization of human acute monocytic leukemic cell line SHI-1. Chinese-German Journal of Clinical Oncology, 2011, 10, 726-729.	0.1	1
66	Using Both Lactic Dehydrogenase Levels and the Ratio of Involved to Uninvolved Free Light Chain Levels as Risk Factors Improves Risk Assessment in Patients With Newly Diagnosed Multiple Myeloma. American Journal of the Medical Sciences, 2018, 355, 350-356.	1.1	1
67	Hemophagocytic lymphohistiocytosis and congenital factor VII deficiency: a case report. BMC Medical Genetics, 2018, 19, 163.	2.1	1
68	A Novel e8a2 <i>BCR-ABL1</i> Fusion Transcript without Insertion Sequence in a Patient with Chronic Myeloid Leukemia. Annals of Laboratory Medicine, 2018, 38, 169-171.	2.5	1
69	Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. , 2020, 18, 844.		1
70	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. Blood, 2020, 136, 38-38.	1.4	1
71	Different manifestations of patients with inhibitors against prothrombin and thrombin. Journal of Thrombosis and Thrombolysis, 2020, 49, 164-167.	2.1	0
72	Exploring the determinants that influence hospital costs of induction therapy for acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1211-1218.	1.3	0

Χιαομίαν Ζημ

#	Article	IF	CITATIONS
73	Correlation of Altered Expression of RIZ1 to Diagnosis, Risk Stratification, and Disease Progression in 56 Acute Leukemia Patients Blood, 2009, 114, 2627-2627.	1.4	0
74	The Interaction of Tumor Cells and Myeloid-Derived Suppressor Cells in Chronic Myelogenous Leukemia. Blood, 2019, 134, 1636-1636.	1.4	0
75	Comparison of Subcutaneous Injection Versus Intravenous Infusion of Cytarabine for Induction Therapy in Young Adult Acute Myeloid Leukemia: Results of a Prospective, Multicenter, Noninferiority, Randomized Trial. Blood, 2020, 136, 4-4.	1.4	0